Pipeline Speed Bump Doesn't Shake AstraZeneca's $80 Billion Revenue Ambition
AstraZeneca Plc (NASDAQ: AZN ) on Monday posted mixed second-quarter 2026 results, beating Wall Street’s earnings estimates while falling short on revenue. The drugmaker also reported disappointing late-stage trial results for two experimental therapies, including a Phase 3 study of Ultomiris. AstraZeneca Beats Earnings Estimates, Misses Revenue Expectations The company posted revenue of $15.384 billion, up 6% year over year, or 5% at constant currency (CC), missing the consensus estimate of $15.459 billion. Adjusted earnings came in at $2.63 per share, ahead of expectations of $2.48. AstraZeneca’s oncology portfolio accounted for 48% of product revenue, rising 16% year over year, or 15% CC, to $7.33 billion. Tagrisso sales increased 7% (6% CC) to $1.94 billion. Imfinzi revenue rose 27% to $1.85 billion, Calquence sales climbed 17% (16% CC) to $1.02 billion, and Enhertu re...
AstraZeneca Plc (NASDAQ: AZN ) on Monday posted mixed second-quarter 2026 results, beating Wall Street’s earnings estimates while falling short on revenue. The drugmaker also reported disappointing late-stage trial results for two experimental therapies, including a Phase 3 study of Ultomiris. 459 billion. 48.
33 billion. 94 billion. 02 billion, and Enhertu revenue jumped 33% (31% CC) to $888 million. 77 billion, representing 18% of product sales, but declined 18% at constant currency.
804 billion. 43 billion. Symbicort sales fell 6% (-8%) to $671 million, while Fasenra revenue grew 14% (13% CC) to $570 million. 31 billion.
Pascal Soriot, CEO, AstraZeneca, said, “We are on track to deliver our $80bn Total Revenue ambition, which assumes successes and setbacks. ” For 2026, AstraZeneca reiterated its guidance, expecting total revenue to grow by a mid- to high-single-digit percentage and core earnings per share to increase by a low double-digit percentage.
Read Also: Ionis, AstraZeneca Stumble in ATTR-CM Trial as Rivals Stand to Gain Ultomiris Misses Primary Endpoint In Phase 3 HSCT-TMA Study AstraZeneca also shared high-level results from the ALXN1210-TMA-313 Phase 3 trial of Ultomiris in patients aged 12 years or older who have thrombotic microangiopathy (TMA) after hematopoietic stem cell transplant (HSCT). TMA is a serious condition where microscopic blood clots form in tiny blood vessels. The study showed that Ultomiris (ravulizumab) did not achieve statistical significance for the primary endpoint of event-free survival through 26 weeks compared to placebo. 4% at 52 weeks, as previously disclosed.
The company is advancing regulatory filings for Ultomiris in pediatric patients with HSCT-TMA, based on these results and data from ALX-TMA-502, an external control study, which further supports clinically meaningful benefit on overall survival. The company said that Ultomiris showed a trend toward treatment benefit in adults and adolescents with HSCT-TMA at 26 weeks compared to placebo. Discussions with health authorities are ongoing regarding the interpretation of these data.
Sone-Ve Improves Overall Survival But Falls Short On PFS The European drug giant on Monday also released high-level results from the CLARITY-Gastric01 global Phase 3 trial of sonesitatug vedotin (Sone-Ve) as later-line treatment for advanced gastric cancers. 2) expression on at least 25% of tumor cells at any staining intensity. Sone-Ve demonstrated a statistically significant and highly clinically meaningful improvement in overall survival (OS) versus investigator’s choice of therapy.
For the other dual primary endpoint of progression-free survival, results showed a trend toward improved PFS in patients treated in the 2nd- and later-line setting but did not reach statistical significance. Sone-Ve was well tolerated, and its profile was consistent with the known safety profile of Sone-Ve, with no new safety signals identified. 80 during premarket trading on Monday, according to Pro data. Photo by Robert Way via Shutterstock Read Also: Michael Burry Says Wall Street Has Turned on Big Tech's AI Spending: 'The Market Has Voted'